Please use this identifier to cite or link to this item:
https://doi.org/10.7554/elife.57683
DC Field | Value | |
---|---|---|
dc.title | EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma | |
dc.contributor.author | Pal, Ananya | |
dc.contributor.author | Leung, Jia Yu | |
dc.contributor.author | Ang, Gareth Chin Khye | |
dc.contributor.author | Rao, Vinay Kumar | |
dc.contributor.author | Pignata, Luca | |
dc.contributor.author | Lim, Huey Jin | |
dc.contributor.author | Hebrard, Maxime | |
dc.contributor.author | Chang, Kenneth TE | |
dc.contributor.author | Lee, Victor KM | |
dc.contributor.author | Guccione, Ernesto | |
dc.contributor.author | Taneja, Reshma | |
dc.date.accessioned | 2020-12-07T06:01:21Z | |
dc.date.available | 2020-12-07T06:01:21Z | |
dc.date.issued | 2020-11-30 | |
dc.identifier.citation | Pal, Ananya, Leung, Jia Yu, Ang, Gareth Chin Khye, Rao, Vinay Kumar, Pignata, Luca, Lim, Huey Jin, Hebrard, Maxime, Chang, Kenneth TE, Lee, Victor KM, Guccione, Ernesto, Taneja, Reshma (2020-11-30). EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma. eLife 9. ScholarBank@NUS Repository. https://doi.org/10.7554/elife.57683 | |
dc.identifier.issn | 2050084X | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/184560 | |
dc.description.abstract | <jats:p>Wnt signaling is down-regulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of differentiation. Epigenetic mechanisms leading to its suppression are unknown and could pave the way towards novel therapeutic modalities. We demonstrate that EHMT2 suppresses canonical Wnt signaling by activating expression of the Wnt antagonist <jats:italic>DKK1</jats:italic>. Inhibition of EHMT2 expression or activity in human ERMS cell lines reduced <jats:italic>DKK1</jats:italic> expression and elevated canonical Wnt signaling resulting in myogenic differentiation <jats:italic>in vitro</jats:italic> and in mouse xenograft models <jats:italic>in vivo</jats:italic>. Mechanistically, EHMT2 impacted Sp1 and p300 enrichment at the <jats:italic>DKK1</jats:italic> promoter. The reduced tumor growth upon EHMT2 deficiency was reversed by recombinant DKK1 or LGK974, which also inhibits Wnt signaling. Consistently, among thirteen drugs targeting chromatin modifiers, EHMT2 inhibitors were highly effective in reducing ERMS cell viability. Our study demonstrates that ERMS cells are vulnerable to EHMT2 inhibitors and suggest that targeting the EHMT2-DKK1-b-catenin node holds promise for differentiation therapy.</jats:p> | |
dc.publisher | eLife Sciences Publications, Ltd | |
dc.source | Elements | |
dc.type | Article | |
dc.date.updated | 2020-12-04T08:51:00Z | |
dc.contributor.department | DEPT OF BIOCHEMISTRY | |
dc.contributor.department | PATHOLOGY | |
dc.contributor.department | PHYSIOLOGY | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.7554/elife.57683 | |
dc.description.sourcetitle | eLife | |
dc.description.volume | 9 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
elife-57683-v2.pdf | Accepted version | 23.42 MB | Adobe PDF | OPEN | Post-print | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.